---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107064"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:09:57.906833+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phibro Q1 net sales up 40% to $363.9M; raises FY2026 adjusted EBITDA guidance to $230-240M

## Summary
- Net sales $363.9M (+40% YoY); net income $26.5M ($0.65 diluted EPS) vs $7.0M ($0.17) prior year.
- Adjusted diluted EPS $0.73 (doubled from $0.35); adjusted EBITDA $61.9M (+$31.2M YoY).
- Animal Health sales rose 55% to $283.5M, driven by acquired MFA portfolio (+$80.5M incremental).
- FY2026 guidance: Adjusted EBITDA raised to $230-240M (28% growth); net sales reaffirmed $1.43-1.48B.
- Company launched Restoris™ dental gel for dogs; annual meeting reelected all director nominees and approved say-on-pay every 3 years.

## SEC filing metadata
- accession: 0001104659-25-107064
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465925107064/0001104659-25-107064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465925107064/pahc-20251104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107064
- JSON: https://secwatch.observer/filing/0001104659-25-107064.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.